Japan Added as Mogamulizumab PIII Study Site for CTCL Patients: Kyowa Kirin

Kyowa Hakko Kirin said on January 15 that Japan will be added as a site for a PIII study of mogamulizumab in patients with relapsed or refractory Cutaneous T-Cell Lymphoma (CTCL), which is ongoing in the US and Europe. Mogamulizumab...read more